1. Home
  2. TILE vs GENB Comparison

TILE vs GENB Comparison

Compare TILE & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Interface Inc.

TILE

Interface Inc.

HOLD

Current Price

$25.54

Market Cap

1.4B

ML Signal

HOLD

GENB

Generate Biomedicines Inc. Common Stock

N/A

Current Price

$13.79

Market Cap

1.7B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
TILE
GENB
Founded
1973
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Home Furnishings
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.7B
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
TILE
GENB
Price
$25.54
$13.79
Analyst Decision
Buy
Strong Buy
Analyst Count
1
5
Target Price
$36.00
$25.00
AVG Volume (30 Days)
624.4K
510.8K
Earning Date
05-01-2026
05-03-2026
Dividend Yield
0.31%
N/A
EPS Growth
32.43
N/A
EPS
1.96
N/A
Revenue
$1,386,854,000.00
N/A
Revenue This Year
$7.00
N/A
Revenue Next Year
$5.46
N/A
P/E Ratio
$13.08
N/A
Revenue Growth
5.41
N/A
52 Week Low
$17.31
$11.00
52 Week High
$35.11
$13.95

Technical Indicators

Market Signals
Indicator
TILE
GENB
Relative Strength Index (RSI) 36.14 59.01
Support Level $24.72 $11.21
Resistance Level $27.13 N/A
Average True Range (ATR) 0.92 1.10
MACD 0.12 0.14
Stochastic Oscillator 31.22 85.97

Price Performance

Historical Comparison
TILE
GENB

About TILE Interface Inc.

Interface Inc is engaged in the design, production, and sale of carpet tiles. It also provides Luxury Vinyl tiles and rubber flooring. The company mainly targets corporate and noncorporate office markets, including government, education, healthcare, hospitality, and retailers. Its geographical segments include the Americas, Europe, and Asia-Pacific. It has two operating and reportable segments- namely Americas (AMS) and Europe, Africa, Asia and Australia (collectively EAAA). Key revenue is generated from AMS segment. Its products include: ESD, Acoustic, Extreme Wear, and Quick Installation System (nTx).

About GENB Generate Biomedicines Inc. Common Stock

Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.

Share on Social Networks: